ACG
ROIV icon

Anchorage Capital Group’s Roivant Sciences ROIV Stock Holding History

Anchorage Capital Group’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,832,642
Closed -$54.5M – 6
2025
Q2 		$54.5M Hold
4,832,642
– – 21.05% 3
2025
Q1 		$48.8M Hold
4,832,642
– – 19.5% 3
2024
Q4 		$57.2M Hold
4,832,642
– – 20.12% 3
2024
Q3 		$55.8M Hold
4,832,642
– – 14.6% 3
2024
Q2 		$51.1M Hold
4,832,642
– – 15.77% 3
2024
Q1 		$50.9M Hold
4,832,642
– – 13.26% 4
2023
Q4 		$54.3M Hold
4,832,642
– – 6.46% 5
2023
Q3 		$56.4M Hold
4,832,642
– – 5.1% 6
2023
Q2 		$48.7M Hold
4,832,642
– – 4.3% 7
2023
Q1 		$35.7M Hold
4,832,642
– – 5.51% 7
2022
Q4 		$38.6M Hold
4,832,642
– – 4.95% 8
2022
Q3 		$15.6M Hold
4,832,642
– – 1.39% 14
2022
Q2 		$19.7M Hold
4,832,642
– – 1.97% 13
2022
Q1 		$23.9M Buy
+4,832,642
New +$31.9M 1.62% 12

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

Anchorage Capital Group's ROIV Position: Q3 2025 in Review

Anchorage Capital Group sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 4,832,642 shares — an estimated $54.5M sold.

Anchorage Capital Group first reported a position in ROIV in Q1 2022 and held it in 14 quarters. The position peaked at $57.2M in Q4 2024. 338 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Anchorage Capital Group reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
  • Anchorage Capital Group sold 4,832,642 Roivant Sciences shares in Q3 2025, an estimated $54.5M.
  • Anchorage Capital Group first reported a position in Roivant Sciences in Q1 2022 and held it in 14 quarters.
  • Anchorage Capital Group's Roivant Sciences position peaked at $57.2M in Q4 2024.
  • 338 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Anchorage Capital Group's 13F filing for Q3 2025, filed 14 Nov 2025.